John Jacques

John Jacques has a diverse work experience in the field of regulatory affairs. John is currently a Co-Founder at Nucleo since January 2021. Prior to this, they worked as an Associate Director of Regulatory Affairs at CSL Behring starting from September 2019.

From October 2015 to August 2019, John served as a Director & Co-Founder of LirPharm and also worked as a Regulatory Affairs Consultant. In addition, they held the role of Interim Vice President for Drug Regulatory Affairs & Compliance at Merus Labs International Inc. from December 2015 to June 2017.

Before that, from September 2013 to September 2015, John was the OUS Regulatory Affairs Director at Mallinckrodt Autoimmune and Rare Disease Division (formerly Questcor). John also worked as a Regulatory Affairs Consultant at Aspen Healthcare FZ LLC, Aspen Europe GmbH, and Aspen Pharma Trading Limited from November 2010 to April 2014.

Prior to their consultancy roles, John served as a Regulatory Consultant from April 2006 to October 2010. John also held the position of Regulatory Affairs Director at IVAX Pharmaceuticals sro from an undisclosed period in 2002 to 2006.

John's early career includes a long tenure as the Group Analytical Development & CMC Registration Manager at Ivax Pharmaceuticals UK, starting from an unknown date in 1989 until 2002.

John Jacques completed a BSc in Pharmaceutical Sciences from the University of Greenwich from 1991 to 1994. John then pursued further education at The University of Manchester from 1997 to 2002, where they obtained an MSc in Pharmaceutical Technology under the PIAT program.